These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26845942)

  • 21. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 23. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C.
    Zeuzem S
    Antivir Ther; 2006; 11(2):267-71. PubMed ID: 16640108
    [No Abstract]   [Full Text] [Related]  

  • 25. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 26. Challenges and successes in developing new therapies for hepatitis C.
    De Francesco R; Migliaccio G
    Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-resistant viral hepatitis.
    Wright M; Main J; Thomas HC
    J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
    [No Abstract]   [Full Text] [Related]  

  • 28. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
    Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F; Collaborators S
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis: HCV virologic response--new nomenclature recommendations.
    Pol S
    Nat Rev Gastroenterol Hepatol; 2012 Nov; 9(11):619-20. PubMed ID: 22926152
    [No Abstract]   [Full Text] [Related]  

  • 30. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 31. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 32. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
    Schmitz J
    Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
    Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
    Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of novel treatments for hepatitis C.
    Webster DP; Klenerman P; Collier J; Jeffery KJ
    Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 36. The design of drugs for HIV and HCV.
    De Clercq E
    Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
    Meanwell NA; Watkins WJ
    J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
    [No Abstract]   [Full Text] [Related]  

  • 39. An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
    Evans KA; Chai D; Graybill TL; Burton G; Sarisky RT; Lin-Goerke J; Johnston VK; Rivero RA
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2205-8. PubMed ID: 16455253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.